[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"no-reflow-phenomenon\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:no-reflow-phenomenon":64},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,49,79,107,130,158,186],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100634216","phase-4-adenosine-pre-medication-in-primary-percutaneous-coronary-intervention-100634216",false,"NCT07536802","Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention","Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention: A Randomized Control Trial","AMPACT","Inclusion Criteria:\n\n* All patients with acute STEMI undergoing primary PCI\n* Patients of either sex, ≥18 years of age.\n\nExclusion Criteria:\n\n* STEMI patients with cardiogenic shock at presentation\n* Patients with heart block\n* Allergy to adenosine\n* Patients refuse to give consent for participation","ALL","18 Years","80 Years",{"count":21,"type":22},1148,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","Primary objective of the study is to evaluate the impact of adenosine pre-medication on incidence of slow flow\u002Fno-reflow after primary percutaneous coronary intervention.",[28,29,30,31],"ST-Segment Elevation Myocardial Infarction (STEMI)","No-Reflow Phenomenon","Coronary Slow Flow","Acute Myocardial Infarction",[33,34,28,29,30,35],"Adenonsine","Primary Percutaneous Coronary Intervention (Primary PCI)","Myocardial Reperfusion","RECRUITING","2026-04-17",{"date":39,"type":40},"2026-04-22","ACTUAL",{"date":42,"type":40},"2025-06-01",{"date":44,"type":22},"2026-12-31",{"name":46,"class":47},"National Institute of Cardiovascular Diseases, Pakistan","OTHER",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100634025","investigation-of-brain-blood-flow-changes-in-acute-ischemic-stroke-patients-after-successful-endovascular-thrombectomy-100634025","NCT07534319","Investigation of Brain Blood Flow Changes in Acute Ischemic Stroke Patients After Successful Endovascular Thrombectomy","RESTORE-AIS","Inclusion Criteria:\n\n* Male and female subjects \\>18 years old.\n* Acute ischemic stroke related to a new occlusion of the internal carotid artery, middle cerebral artery (M1- and\u002For M2-segment), or both.\n* Eligibility and performance of endovascular thrombectomy.\n* Achievement of successful recanalization, defined as mTICI score ≥2b\n* Written informed consent of the patient or when the patient is not able to participate in the consenting procedure, the written authorization of a family member. Foreign speaking patients should be included by a person with sufficient German language proficiency to act as a translator.\n\nExclusion Criteria:\n\n* Documented evidence or a confirmed willingness of the patient not to participate in any scientific study.\n* Standard contraindications for MRI, such as pacemaker, metallic prothesis, glaucoma, metallic tattoo dyes, verbal confirmed pregnancy. Unwilling or unable to cooperate with breathing manoeuvres.\n* Major cardiopulmonary diseases, such as severe uncontrolled asthma bronchiale, severe chronic obstructive lung disease (i.e., GOLD stage ≥III), diffuse interstitial lung disease, pulmonary embolism, acute\u002Fsubacute myocardial infarction, or severe heart failure (i.e., NYHA class ≥III).\n* Symptomatic increased intracranial pressure.\n* Presence of intracranial haemorrhage type ≥2 according to the Heidelberg classification.\n* New onset of seizure.",{"count":57,"type":22},100,"OBSERVATIONAL","Introduction:\n\nEndovascular thrombectomy (EVT) is an effective treatment strategy to mitigate the ischemic tissue damage caused by the acute cerebral large-vessel occlusion. However, in clinical practice, nearly half of the patients do not experience adequate neurological improvement despite successful recanalization - a phenomenon termed reperfusion failure or clinically ineffective reperfusion. Given the clinical relevance of this phenomenon and the absence of a standardized imaging diagnostic method to identify it, our project aims to explore the potential role of blood oxygenation-level dependent cerebrovascular reactivity (BOLD-CVR) as novel imaging biomarker for studying reperfusion failure.\n\nStudy population:\n\nAdult patients with acute ischemic stroke of the ICA, MCA or with tandem occlusion who have undergone a successful recanalization, described as mTICI score ≥2b.\n\nObjective(s):\n\nPrimary objective: to longitudinally observe blood flow changes derived from BOLD-CVR imaging following successful endovascular thrombectomy in patients with large-vessel occlusion acute ischemic stroke (LVO-AIS) during the early post-treatment phase and assess their association with clinical outcome 90 days post-EVT.\n\nSecondary objective: to compare BOLD-CVR findings with those obtained from the clinical standard dynamic susceptibility contrast (DSC) MR perfusion imaging acquired in the same examination session as well as other imaging techniques included in the standard post-treatment imaging protocol at our institution.\n\nOutcomes:\n\nClinical outcomes:\n\n* 90-day functional outcome.\n* Functional outcome at hospital discharge.\n* Neurological deterioration during hospitalization.\n* Radiologically confirmed haemorrhagic transformation within the reperfused tissue.\n* Radiologically confirmed infarct lesion progression within the reperfused tissue.\n* Additionally, DSC MR perfusion imaging parameters and other standard hemodynamic imaging parameters will be considered as imaging outcomes\n\nStudy design:\n\nSingle-center prospective observational cohort study\n\nMeasurements and procedures:\n\nIncluded patients will undergo a total of 3 BOLD-CVR examinations: 72 hours, 7 days, and 90 days after EVT. Participation in the final examination will mark the end of the subject's involvement in the study. Clinical outcomes will be prospectively collected as per established institutional patient management protocols: during hospitalization, at discharge, and at the cerebrovascular outpatient clinic at 3 months.\n\nNumber of Participants:\n\nTarget sample size: 100 patients\n\nGiven the observational study design and exploratory nature of this project, no sample size calculation can be performed. The provided target sample size (N = 100) has been estimated considering the inclusion of as many consecutive subjects as possible.\n\nStudy period: 2.5 years The investigators aim to enroll a target sample size of 100 patients over a period of 2.5 years. This translates to an inclusion of 3-4 patients per month, with the last three months allocated for the follow-up of the last included patients.\n\nStudy Centre:\n\nClinical Neuroscience Center, Department of Neurosurgery, University Hospital Zurich\n\nStatistical Considerations:\n\nThe association between BOLD-CVR findings and clinical outcomes will be investigated using regression analyses.",[61,62,63,64],"Acute Cerebrovascular Accident","Thrombectomy","Cerebral Revascularization","No Reflow Phenomenon",[66,62,67,63,64,68,69],"Acute Ischemic Stroke","Reperfusion Failure","BOLD-CVR","Advanced Haemodynamic Imaging","2026-04-09",{"date":72,"type":40},"2026-04-16",{"date":42,"type":40},{"date":75,"type":22},"2027-12-01",{"name":77,"class":47},"University of Zurich",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":4},"100607996","phase-4-rivaroxaban-for-slow-coronary-flow-after-pci-in-stemi-100607996","NCT07195812","Rivaroxaban for Slow Coronary Flow After PCI in STEMI","Evaluation of the Efficacy and Safety of Rivaroxaban in Improving Slow Coronary Flow After Percutaneous Coronary Intervention in STEMI Patients: A Multicenter, Prospective,Randomized, Controlled Study","Inclusion Criteria:\n\n* Age ≥ 18 years, regardless of gender;\n* Patients with ST-segment elevation myocardial infarction (STEMI) (meeting the diagnostic criteria of the 2019 Chinese \"Guidelines for the Diagnosis and Treatment of Acute ST-Segment Elevation Myocardial Infarction\");\n* Patients undergoing percutaneous coronary intervention (PCI);\n* Patients with slow flow after PCI (TIMI flow grade \\> 0 but \\\u003C 3);\n* Signed informed consent form and willingness to comply with follow-up.\n\nExclusion Criteria:\n\n* Presence of malignant tumors or diseases with a life expectancy of less than 1 year;\n* Coagulation disorders, diagnosed or suspected hematological diseases (excluding mild or moderate anemia);\n* Thrombocytopenia (platelet count \\\u003C 100 × 10⁹\u002FL); history of severe gastrointestinal diseases or peptic ulcers; active bleeding within the past 3 months or major surgery history; history of intracranial hemorrhage or intracranial aneurysm;\n* History of cerebral hemorrhage or ischemic stroke within the past 6 months;\n* Patients with cardiogenic shock; systemic infections or immune system diseases; confirmed, highly suspected, or unable to rule out aortic dissection; severe uncontrolled hypertension (systolic blood pressure \\> 180 mmHg and\u002For diastolic blood pressure \\> 110 mmHg);\n* Current use of rivaroxaban or requiring long-term anticoagulation therapy (e.g., atrial fibrillation);\n* Patients with renal insufficiency (eGFR \\\u003C 15 mL\u002Fmin\u002F1.73m²) or hepatic insufficiency (Child-Pugh Class B or C);\n* Lactating or pregnant women, or women of childbearing potential unable to use effective contraception during the study period;\n* Patients with any contraindications or allergies to rivaroxaban, aspirin, clopidogrel, or ticagrelor;\n* Participation in other clinical trials within the past 3 months;\n* Other conditions deemed unsuitable for participation by the investigator.",{"count":87,"type":22},60,[25],"The goal of this clinical trial is to learn if drug Rivaroxaban works to improve slow flow in STEMI patients after PCI in adults. It will also learn about the safety of drug Rivaroxaban. The main questions it aims to answer are:\n\nDoes drug Rivaroxaban Reduce the Corrected TIMI Frame Count (cTFC) in 1 Week After PCI ?\n\nResearchers will compare Combination therapy with rivaroxaban (2.5 mg administered twice daily), aspirin (100 mg administered daily), and clopidogrel (75 mg administered daily) to Dual Antiplatelet Therapy to see if drug Combination therapy with rivaroxaban, aspirin works to treat Slow Flow in STEMI Patients After PCI.\n\nParticipants will:\n\nTake drug Combination therapy with rivaroxaban (2.5 mg administered twice daily), aspirin (100 mg administered daily), and clopidogrel (75 mg administered daily) or Dual Antiplatelet Therapy every day for 1 months.\n\nVisit the clinic in 7 days、30 days and 365 days for checkups and tests.",[91,29],"ST Elevation Myocardial Infarction",[93,91,94,29,95,96],"Rivaroxaban","Slow Coronary Flow","Antiplatelet Therapy","Percutaneous Coronary Intervention","NOT_YET_RECRUITING","2025-09-25",{"date":100,"type":40},"2025-09-29",{"date":102,"type":22},"2025-10",{"date":104,"type":22},"2028-05",{"name":106,"class":47},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":115,"targetDuration":117,"studyType":58,"phases":4,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":4},"100603128","validation-of-new-biomarkers-for-predicting-no-reflow-in-stemi-patients-undergoing-primary-pci-100603128","NCT07132489","Validation of New Biomarkers for Predicting No-Reflow in STEMI Patients Undergoing Primary PCI","Validation of Novel Metabolic, Inflammatory, and Hepatic-Renal Biomarkers-HbA1c\u002FC-peptide Ratio, Neutrophil\u002FHDL Ratio, and ALBI Score-for Predicting the No-Reflow Phenomenon After Primary PCI in Patients With STEMI.","VaBiNoR","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Suitable for and undergoing timely primary PCI based on symptoms and clinical judgment\n* Provision of informed consent\n\nExclusion Criteria:\n\n* History of previous MI, PCI, or CABG\n* Known chronic inflammatory or autoimmune diseases\n* Advanced renal or hepatic failure\n* Active infection or malignancy at presentation\n* Incomplete data or refusal to consent",{"count":116,"type":22},114,"1 Month","To evaluate the diagnostic value of the selected emerging biomarkers in predicting the no-reflow phenomenon among patients presenting with STEMI undergoing primary PCI. These biomarkers include:\n\nHbA1c\u002FC-peptide ratio\n\nAlbumin-bilirubin (ALBI) score.\n\nNeutrophil\u002FHDL ratio",[120,64],"Myocardial Infarction","2025-08-25",{"date":123,"type":40},"2025-08-29",{"date":125,"type":22},"2025-09-01",{"date":127,"type":22},"2028-12-01",{"name":129,"class":47},"Assiut University",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":23,"phases":139,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":78},"100581227","phase-3-the-investigator-administers-intracoronary-adrenaline-via-the-catheter-in-stemi-patients-during-primary-pci-after-flow-restoration-and-before-stenting-and-studies-its-effect-in-prevention-of-no-reflow-100581227","NCT06847568","The Investigator Administers Intracoronary Adrenaline Via the Catheter in STEMI Patients During Primary PCI, After Flow Restoration and Before Stenting, and Studies Its Effect in Prevention of No Reflow","Role of Catheter Administered Intracoronary Epinephrine in Prevention of No-Reflow in STEMI Patients Undergoing Primary Percutaneous Coronary Intervention","Inclusion Criteria:\n\n1. Patients who are 18 years or older\n2. Patients presenting with acute coronary syndrome with ECG criteria diagnostic of STEMI (according to the universal definition of myocardial infarction) within 12 hours from the onset of symptoms and treated by successful primary PCI.\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years\n2. Pregnant females.\n3. Patients refused to give consent.\n4. Patients who had normal coronary angiography.\n5. Patients who had CTO lesions.\n6. Patients who have SCAD.\n7. Patients who developed dissection or mechanical complication during the procedure.\n8. Patients presenting with cardiogenic shock.\n9. Cardiomyopathies\n10. Contraindications to epinephrine as HTN with SBP \\>180 mmHg or DBP\\>110 mmHg, clinically significant arrhythmia (Atrial fibrillation with rapid ventricular rate, ventricular tachycardia, or ventricular fibrillation) prior to PCI, known allergy to epinephrine.",{"count":138,"type":22},1000,[140],"PHASE3","The aim of this work is to study the role of intracoronary adrenaline administration as a preventive tool for no reflow in patients undergoing primary PCI.\n\nThe main question it aims to answer is:\n\nDo prohylcatic intrcoronary adrenaline reduce the incidence of no reflow without increaing risk of arrhythmia in primary PCI?\n\nThe procedure will be performed by expert operators. All patients will receive the guidelines-directed recommendations of intervention of STEMI patients.\n\nStudy group wil receive Intracoronary 10 mcg adrenaline via the guiding catheter after restoration of epicardial coronary flow of the culprit vessel and achievement of TIMI I flow either after wiring and\u002For passage of a deflated balloon and\u002For PTCA with a small balloon, and\u002For use of thrombus aspiration and before stenting.\n\nAll steps in the Cath-lab will be described in detail:\n\nThe primary end points will be improvement in coronary flow, as assessed by TIMI (Thrombolysis in Myocardial Infarction) flow, and myocardial blush.\n\nSecondary end points will be in-hospital mortality and major adverse cardiac events.",[143,64],"ST Segment Elevation Myocardial Infarction (STEMI)",[145,146,147,148],"STEMI","No-reflow","Adrenaline","Prophylaxis","2025-03-07",{"date":151,"type":40},"2025-03-11",{"date":153,"type":40},"2024-04-01",{"date":155,"type":22},"2026-04-30",{"name":157,"class":47},"Ain Shams University",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":17,"minAge":165,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":23,"phases":168,"briefSummary":169,"conditions":170,"keywords":172,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":78},"100472123","phase-4-a-study-to-evaluate-the-impact-of-pre-procedural-intracoronary-nicorandil-injection-to-prevent-reduction-of-decreased-timi-flow-in-patients-who-undergoing-percutaneous-coronary-intervention-for-the-coronary-artery-disease-100472123","NCT05427786","A Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT ReductioN of DecREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery Disease","A Randomized, Open Label, Parallel-group Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT ReductioN of DecREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery Disease","Inclusion Criteria:\n\n1. Over 19 years old\n2. Patients who agree to the study plan and clinical follow-up plan, voluntarily decide to participate in this study, and consent in writing to the consent to use information\n3. Patients who underwent NIRS-IVUS guided coronary stent surgery for coronary artery disease\n\nExclusion Criteria:\n\n1. Patients with TIMI ≤ 2 before coronary intervention\n2. Subjects with known hypersensitivity or contraindications to the following drugs or substances: heparin, aspirin, clopidogrel, ticagrelor, prasugrel, rosuvastatin, ezetimibe, evolocumab, lansoprazole, cobalt chromium, stainless steel nickel And contrast agents (however, even a subject who is hypersensitive to contrast agents can register if they can be controlled by steroids and pheniramine, except for known anaphylaxis.)\n3. Pregnant women, lactating women, or women of childbearing age who plan to become pregnant during this study\n4. Subjects who plan to have surgery to stop antiplatelet drugs within 6 months from registration\n5. Those whose surviving life is expected to be less than 1 year\n6. Subjects who visited the hospital due to cardiogenic shock and are predicted to have low survival probability based on medical judgment","19 Years",{"count":167,"type":22},460,[25],"The aim of this study was to determine the effect of intra-coronary administration of nicorandil on the prevention of lowering of coronary blood flow for high-risk plaque lesions defined as the high value of lipid core burden index in patients with coronary artery disease who require stent treatment.",[29,171,96],"Coronary Artery Disease",[173,174,175,176],"Nicorandil","No-reflow phenomenon","lipid core burden index","near-infrared spectroscopy","2024-10-08",{"date":179,"type":40},"2024-10-10",{"date":181,"type":40},"2022-12-14",{"date":183,"type":22},"2026-12",{"name":185,"class":47},"Korea University Anam Hospital",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":193,"targetDuration":4,"studyType":23,"phases":195,"briefSummary":197,"conditions":198,"keywords":200,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":4},"100469495","upfront-premedication-for-reduction-of-microvascular-obstruction-and-no-reflow-in-treating-st-segment-elevation-myocardial-infarction-100469495","NCT05393557","Upfront Premedication For Reduction of Microvascular Obstruction and No-reflow in Treating ST-segment Elevation Myocardial Infarction","UPFRONT-STEMI","Inclusion Criteria:\n\n* STEMI patients with time from symptom onset of \\\u003C 24 hours duration.\n* Large thrombus burden confirmed after initial wiring.\n* Radial vascular access.\n\nExclusion Criteria:\n\n* STEMI patients receiving successful fibrinolytic therapy.\n* TIMI flow ≥ 1 or TIMI thrombus grade ≤ 3 at initial wiring.\n* Refusal to participate int the study, or unable to be consented (unconscious or comatose patients).\n* Femoral access.\n* Previous infarction in the same territory.\n* Patients receiving PTCA only for acute reperfusion and planned for CABG.\n* Patients with known intolerance or contraindications for CMR, such as claustrophobic or those with mechanical heart valve prothesis, or implantable non-conditional heart rhythm devices.",{"count":194,"type":22},626,[196],"NA","Angiographic no-reflow during primary PCI procedures occurs at relatively high rate (25%) and is associated with worsening of long term morbidity and mortality. The exact mechanism of no-reflow is not fully understood, yet it is believed to be multifactorial including microvascular plugging with activated platelets and thrombotic debris in addition to the microvascular dysfunction from the ischaemia-reperfusion injury.\n\nDespite a theoretical advantage of glycoprotein IIb\u002FIIIa inhibitors (GPi) (like; Tirofiban) to suppress the intense platelets' activation\u002Freaction; their use did not lead to a significant net benefit, because it was opposed by increased risk of bleeding.\n\nHowever, the bleeding that plagued GPi use was predominantly related to vascular access in the era femoral approach was the default. Moreover, there are some recent data suggesting that small intracoronary bolus of GPi was non-inferior to intravenous bolus-infusion dose with less bleeding events.\n\nThis study plans to assess upfront premedication with small doses of GPi + Nitroglycerin ± Verapamil, with staged restoration of flow (repeated balloon inflation) to reduce angiographic no-reflow and CMR assessed microvascular occlusion (MVO).",[145,199,29],"Large Thrombus Burden",[201,145,202,203,204],"No reflow","Glycoprotein inhibitor","repeated intermittent balloon inflation","reperfusion injury","2023-08-30",{"date":207,"type":40},"2023-08-31",{"date":209,"type":22},"2024-01-01",{"date":211,"type":22},"2026-11-30",{"name":213,"class":47},"Cairo University"]